(Alliance News) - C4X Discovery Holdings PLC on Monday said it is forming a drug discovery advisory network chaired by "renowned industry veteran" Robin Carr.
Shares in C4X were up 3.8% at 39.95 pence in London at midday.
Carr has held a number of senior roles, including at GlaxoSmithKline PLC, where he was he was senior vice president of Drug Design & Selection.
The advisory network is intended to bring experts in the field of drug discovery and development to the company to enhance its capabilities, and to act as company ambassadors within the industry.
C4X Chief Executive Clive Dix said: "We are delighted to announce the formation of our advisory network and to be working closely with prestigious world leading experts in drug discovery. As part of our strategy to become the world's most productive drug discovery company, we are continually enhancing both our network and expertise. As international thought leaders, the advisory network's deep industry expertise will enable us to accelerate progress of our portfolio and we are particularly proud that Robin will be chair. Under Robin's guidance, we believe the advisory network will advance our vision and reputation within the industry."
Glaxosmithkline (GSK)
